Daniel Alkon

Presidente presso NEUROTROPE, INC.

Patrimonio netto: 6 275 $ in data 30/04/2024

81 anni

Health Technology

Consumer Services

Electronic Technology

Posizioni attive di Daniel Alkon

Società	Posizione	Inizio	Fine
NEUROTROPE, INC.	Direttore Tecnico/Scientifico/R&S	23/08/2013	-
NEUROTROPE, INC.	Presidente	19/09/2016	-
SYNAPTOGENIX, INC.	Direttore/Membro del Consiglio	07/12/2020	-
	Direttore Tecnico/Scientifico/R&S	-	-
	Presidente	-	-

Società	Posizione	Inizio	Fine
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Direttore Tecnico/Scientifico/R&S	01/01/1999	23/09/2016
West Virginia University	Corporate Officer/Principal	-	01/09/2016
Adaptive Systems, Inc. Adaptive Systems, Inc. Computer Processing HardwareElectronic Technology Adaptive Systems, Inc. manufactures and develops small, high performance modular hardware products for use by the embedded computer industry. It products include 486DX 66MHz, 586-133MHz Processors; System Management; Super I/O, VGA, PCMCIA; and Sound O/S. The company is headquartered in Longmont, CO.	Corporate Officer/Principal	-	-
National Institute of Neurological Disorders & Stroke	Direttore Tecnico/Scientifico/R&S	-	-

University of Pennsylvania	Undergraduate Degree
Cornell University	Doctorate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Chief Tech/Sci/R&D Officer	4
President	2
Corporate Officer/Principal	2

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
SYNAPTOGENIX, INC.	Health Technology

Aziende private	4
Neurotrope, Inc. Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.	Health Technology
Adaptive Systems, Inc. Adaptive Systems, Inc. Computer Processing HardwareElectronic Technology Adaptive Systems, Inc. manufactures and develops small, high performance modular hardware products for use by the embedded computer industry. It products include 486DX 66MHz, 586-133MHz Processors; System Management; Super I/O, VGA, PCMCIA; and Sound O/S. The company is headquartered in Longmont, CO.	Electronic Technology
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Health Technology
National Institute of Neurological Disorders & Stroke	Government